Activation of vitamin D receptor signaling downregulates the expression of nuclear FOXM1 protein and suppresses pancreatic cancer cell stemness

Clinical Cancer Research

Volumn 21, Issue 4, 2015, Pages 844-853

  Li, Zhiwei ^a,b   Jia, Zhiliang ^b   Gao, Yong ^c   Xie, Dacheng ^c,d   Wei, Daoyan ^b   Cui, Jiujie ^b,d   Mishra, Lopa ^b   Huang, Suyun ^b   Zhang, Yanqiao ^a   Xie, Keping ^b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^d SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; FORKHEAD BOX M1 PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; NUCLEAR PROTEIN; SEOCALCITOL; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; FOXM1 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CANCER INHIBITION; CARCINOGENESIS; CARCINOGENICITY; CARCINOMA CELL; CONTROLLED STUDY; CYTOLOGY; EXPERIMENTAL STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSGENICS; VALIDATION STUDY; 3T3 CELL LINE; ANIMAL; CANCER STEM CELL; DISEASE MODEL; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BALB 3T3 CELLS; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CALCITRIOL; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TRANSFECTION;

EID: 84923167556     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2437     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, et al. Recent progress in pancreatic cancer. CA Cancer J Clin 2013; 63: 318-48.
3. Paulson AS, Tran Cao HS, Tempero MA, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology 2013; 144: 1316-26.
4. Hartwig W, Werner J, Jager D, Debus J, Buchler MW. Improvement of surgical results for pancreatic cancer. Lancet Oncol 2013; 14:e476-85.
5. Abel EV, Simeone DM. Biology and clinical applications of pancreatic cancer stem cells. Gastroenterology 2013; 144: 1241-8.
6. Zheng L, Xue J, Jaffee EM, Habtezion A. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology 2013; 144: 1230-40.
7. Stanger BZ, Hebrok M. Control of cell identity in pancreas development and regeneration. Gastroenterology 2013; 144: 1170-9.
8. Wierstra I. The transcription factor FOXM1 (Forkhead box M1): proliferation-specific expression, transcription factor function, target genes, mouse models, and normal biological roles. Adv Cancer Res 2013; 118: 97-398
9. Kalin TV, Ustiyan V, Kalinichenko VV. Multiple faces of FoxM1 transcription factor: lessons from transgenic mouse models. Cell Cycle 2011; 10: 396-405.
10. Raychaudhuri P, Park HJ. FoxM1: a master regulator of tumor metastasis. Cancer Res 2011; 71: 4329-4333.
11. Halasi M, Gartel AL. FOX(M1) news-it is cancer. Mol Cancer Ther 2013; 12: 245-54.
12. Huang C, Du J, Xie K. FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesis. Biochim Biophys Acta 2014; 1845: 104-16.
13. Wang Z, Ahmad A, Li Y, Banerjee S, Kong D, Sarkar FH. Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat Rev 2010; 36: 151-6.
14. Koo CY, Muir KW, Lam EW. FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta 2012; 1819: 28-37.
15. Wang Z, Banerjee S, Kong D, Li Y, Sarkar FH. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 2007; 67: 8293-8300.
16. Huang C, Qiu Z, Wang L, Peng Z, Jia Z, Logsdon CD, et al. A novel FoxM1-Caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Cancer Res 2012; 72: 655-65.
17. Shah S, Islam MN, Dakshanamurthy S, Rizvi I, Rao M, Herrell R, et al. The molecular basis of vitamin D receptor and β-catenin crossregulation. Mol Cell 2006; 21: 799-809.
18. Larriba MJ, Gonzalez-Sancho JM, Barbachano A, Niell N, Ferrer-Mayorga G, Munoz A. Vitamin D is a multilevel repressor of Wnt/β-catenin signaling in cancer cells. Cancers (Basel) 2013; 5: 1242-60.
19. Beildeck ME, Islam M, Shah S, Welsh J, Byers SW. Control of TCF-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines. PLoS ONE 2009; 4:e7872.
20. Evans PM, Chen X, Zhang W, Liu C. KLF4 interacts with β-catenin/TCF4 and blocks p300/CBP recruitment by beta-catenin. Mol Cell Biol 2010; 30: 372-81.
21. Kennedy DA, Cooley K, Skidmore B, Fritz H, Campbell T, Seely D. Vitamin d: pharmacokinetics and safety when used in conjunction with the pharmaceutical drugs used in cancer patients: a systematic review. Cancers (Basel) 2013; 5: 255-80.
22. Lin R, Nagai Y, Sladek R, Bastien Y, Ho J, Petrecca K, et al. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol 2002; 16: 1243-56.
23. Wood RJ, Tchack L, Angelo G, Pratt RE, Sonna LA. DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. Physiol Genomics 2004; 17: 122-29.
24. Byers SW, Rowlands T, Beildeck M, Bong YS. Mechanism of action of vitamin D and the vitamin D receptor in colorectal cancer prevention and treatment. Rev Endocr Metab Disord 2012; 13: 31-8.
25. Sakai Y, Demay MB. Evaluation of keratinocyte proliferation and differentiation in vitamin D receptor knockout mice. Endocrinology 2000; 141: 2043-9.
26. Di Rosa M, Malaguarnera M, Nicoletti F, Malaguarnera L. Vitamin D3: a helpful immuno-modulator. Immunology 2011; 134: 123-39.
27. Thorne J, Campbell MJ. The vitamin D receptor in cancer. Proc Nutr Soc 2008; 67: 115-27.
28. Palmer HG, Sanchez-Carbayo M, Ordonez-Moran P, Larriba MJ, Cordon-Cardo C, Munoz A. Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Res 2003; 63: 7799-806.
29. Wang TT, Tavera-Mendoza LE, Laperriere D, Libby E, MacLeod NB, Nagai Y, et al. Large-scale in silico and micro array-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol 2005; 19: 2685-95.
30. Mullin GE, Dobs A. Vitamin d and its role in cancer and immunity: a prescription for sunlight. Nutr Clin Pract 2007; 22: 305-22.
31. Spina CS, Ton L, Yao M, Maehr H, Wolfe MM, Uskokovic M, et al. Selective vitamin D receptor modulators and their effects on colorectal tumor growth. J Steroid Biochem Mol Biol 2007; 103: 757-62.
32. de Lyra EC, da Silva IA, Katayama ML, Brentani MM, Nonogaki S, Goes JC, et al. 25(OH)D3 and 1,25(OH)2D3 629 serum concentration and breast tissue expression of 1alpha-hydroxylase, 24-hydroxylase and Vitamin D receptor in women with and without breast cancer. J Steroid Biochem Mol Biol 2006; 100: 184-92.
33. Zugmaier G, Jäger R, Grage B, Gottardis MM, Havemann K, Knabbe C. Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br J Cancer 1996; 73: 1341-6.
34. Kanemaru M, Maehara N, Chijiiwa K. Antiproliferative effect of 1α,25-dihydroxyvitamin D3 involves upregulation of cyclin-dependent kinase inhibitor p21 in human pancreatic cancer cells. Hepatogastroenterology 2013; 60: 1199-205.
35. Kawa S, Nikaido T, Aoki Y, Zhai Y, Kumagai T, Furihata K, et al. Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines. Br J Cancer 1997; 76: 884-9.
36. Persons KS, Eddy VJ, Chadid S, Deoliveira R, Saha AK, Ray R. Antigrowth effect of 1,25-dihydroxyvitamin D3-3-bromoacetate alone or in combination with 5-amino-imidazole-4-carboxamide-1-beta-4-ribofuranoside in pancreatic cancer cells. Anticancer Res 2010; 30: 1875-80.
37. Ghous Z, Akhter J, Pourgholami MH, Morris DL. Inhibition of hepatocellular cancer by EB1089: in vitro and in vivo study. Anticancer Res 2008; 28: 3757-62.
38. Mouratidis PX, Dalgleish AG, Colston KW. Investigation of the mechanismsbywhich EB1089abrogates apoptosis inducedby9-cisretinoic acid in pancreatic cancer cells. Pancreas 2006; 32: 93-100.
39. Zhang X, Jiang F, Li P, Li C, Ma Q, Nicosia SV, et al. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089. Clin Cancer Res 2005; 11: 323-8.
40. Milliken EL, Zhang X, Flask C, Duerk JL, MacDonald PN, Keri RA. EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer. Cancer Lett 2005; 229: 205-15.
41. Evans TR, Colston KW, Lofts FJ, Cunningham D, Anthoney DA, Gogas H, et al. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer 2002; 86: 680-5.
42. Zhang N, Wei P, Gong A, Chiu WT, Lee HT, Colman H, et al. FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 2011; 20: 427-42.
43. Hendrickson WK, Flavin R, Kasperzyk JL, Fiorentino M, Fang F, Lis R, et al. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol 2011; 29: 2378-85.
44. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 2001; 154: 369-87.
45. Dalhoff K, Dancey J, Astrup L, Skovsgaard T, Hamberg KJ, Lofts FJ, et al. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 2003; 89: 252-7.
46. Cho M, Peddi PF, Ding K, Chen L, Thomas D, Wang J, et al. Vitamin D deficiency and prognostics among patients with pancreatic adenocarcinoma. J Transl Med 2013; 11: 206.
47. Marik R, Fackler M, Gabrielson E, Zeiger MA, Sukumar S, Stearns V, et al. DNA methylation-related vitamin D receptor insensitivity in breast cancer. Cancer Biol Ther 2010; 10: 44-53.
48. Larriba MJ, Martín-Villar E, García JM, Pereira F, Pena C, de Herreros AG, et al. Snail2 cooperates with Snail1 in the repression of vitamin D receptor in colon cancer. Carcinogenesis 2009; 30: 1459-68.
49. Yang H, Zhang Y, Zhou Z, Jiang X, Shen A. Snail-1 regulates VDR signaling and inhibits 1,25(OH)-D(3) action in osteosarcoma. Eur J Pharmacol 2011; 670: 341-6.